Weekly CAF chemotherapy for advanced breast cancer patients

Wei Shou Hwang, Chao A. Hsiung, Wann Sheng Ko, Chang Chung Wang, Jang Yang Chang, Gi Ming Lai, Ruey Kuen Hsieh, Chao Jung Tsao, Li Tzong Chen, Chi Kong Law, Ann Lii Cheng, Sheng F. Fan, Cheng Hwai Tzeng, Tzeon Jye Chiou, Jacqueline Whang-Peng

研究成果: 雜誌貢獻文章同行評審

1 引文 斯高帕斯(Scopus)


In a prospective phase II study, 102 women with advanced breast cancer were treated with low doses of cyclophosphamide, Adriamycin and 5-fluorouracil (CAF) at weekly intervals by intravenous injection. Seventy-five patients were evaluable for treatment response and the overall response rate was 52% (95% confidence interval, 41-63%). Of the evaluable patients, 15% had complete response and 37% had partial response. The median survival after therapy was 15.6 months, the median time to progression was 6.8 months and the median duration of response was 9.1 months. The main toxicities were mild vomiting and moderate myelosuppression. There was only 1 patient who experienced heart failure. Weekly CAF appears to have an efficacy with tolerable side effects comparable to standard CAF with an every-3-week schedule.
頁(從 - 到)293-297
出版狀態已發佈 - 7月 1997

ASJC Scopus subject areas

  • 癌症研究
  • 腫瘤科


深入研究「Weekly CAF chemotherapy for advanced breast cancer patients」主題。共同形成了獨特的指紋。